Knotless Tissue Control Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The knotless tissue control devices market size is expected to grow from USD 0.95 billion in 2025 to USD 1 billion in 2026 and is forecast to reach USD 1.33 billion by 2031 at 5.78% CAGR over 2026-2031. This report is segmented by Product Type (Short-Term, Long-Term Absorbable, Non-Absorbable), Barb Architecture (Unidirectional, Bidirectional), Anchor Design (Loop-End, End-Stopper), Application (General Surgery, Gynecological, Orthopedic, and More), End User (Hospitals, Specialty Clinics, and More), and Geography (North America, Europe, and More). Forecasts are Provided in Value (USD).

Global Knotless Tissue Control Devices Market Trends and Insights

Expansion Of Minimally Invasive And Robotic Soft-Tissue Closure

Robotic surgery is reshaping demand for knotless closure beyond a simple increase in procedure volumes. A retrospective study of more than 220,000 U.S. patients found that use of knotless devices in robotic total hysterectomy rose from 2.9% to 10.4% over 7 years. Use in ventral hernia repair rose from 12.2% to 25.3% during the same observation period. In robotic cardiac surgery, V-Loc barbed sutures reduced left atrial closure time by 31.3%, or 11 minutes compared with 16 minutes for conventional sutures, without a rise in reoperation or major complications. Robotic suites often standardize device protocols during team training, which can make conventional sutures less favored within established workflows. This effect supports the Knotless Tissue Control Devices Market as robotic programs broaden across orthopedics, urology, general surgery, and oncology.

Operating-Room Time And Throughput Economics

The operating-room case for knotless devices rests on time savings that can improve daily capacity. In robotic total hysterectomy, knotless devices reduced adjusted operating-room time by 19.1 minutes. Ventral hernia repair recorded a 17.3-minute reduction in adjusted operating-room time. The reported savings equated to USD 700 to USD 2,158 per hysterectomy case and USD 640 to USD 1,955 per hernia repair case, depending on the operating-room cost applied. A single operating room in an ambulatory surgical center commonly manages 4 to 6 cases each day. Recovering 17 to 19 minutes can allow capacity for an additional case, making the revenue case more direct for these facilities. This operational setting strengthens the Knotless Tissue Control Devices Market, where procurement decisions are closely tied to patient throughput.

Premium Pricing And Access Requirements

Premium pricing remains an access issue for manufacturers pursuing hospital adoption. Barbed knotless devices were indicated at USD 150 to USD 350 per box of 12 to 24 units in U.S. list pricing, although group-purchasing contracts can reduce realized prices. Hospital value-analysis committees review device additions against the clinical and financial return they can demonstrate. A peer-reviewed evaluation reported average savings of USD 48.8 per total knee arthroplasty case for barbed versus traditional sutures. That saving may not always be sufficient for premium-tier procurement in the hospital channel. New FDA-cleared products from India and South Korea entered the U.S. market in 2025, adding price competition against established suppliers.

Other drivers and restraints analyzed in the detailed report include:

• Growth In Surgical Volumes And Outpatient Procedures
• Antibacterial Innovation And High-Tension Closure
• Clinical Consistency, Safety, And Adoption Complexity

Segment Analysis

Non-absorbable polymer devices captured 42.31% of the Knotless Tissue Control Devices Market share in 2025. Their position reflects use in permanent and semi-permanent tissue fixation, especially in orthopedic and cardiovascular procedures where mechanical integrity must remain over time. The material is suited to clinical settings in which degradation would conflict with the functional need for continuing support. Short-term absorbable products form a middle tier for gynecological and general soft-tissue approximation. Their absorption pattern aligns with wound-healing periods of 2 to 6 weeks. Product selection is therefore tied to the anticipated healing profile and the level of mechanical support required after the procedure.

Long-term absorbable devices are forecast to grow at a 6.65% CAGR from 2026 to 2031, the fastest rate in this product classification. The FDA cleared STRATAFIX Symmetric PDS Plus in May 2026 for high-tension applications, including abdominal wall fascia, knee extensor mechanism fascia, deep hip fascia, and ventral hernia closure. The device extension makes long-term absorbable options more relevant for fascia closure. Continued adoption in high-tension anatomy could reduce the long-term weight of non-absorbable products in the mix. The Knotless Tissue Control Devices Market size for long-term absorbable devices is consequently linked to whether surgeons adopt these products in the newly cleared applications.

Unidirectional barbed devices held 58.24% of the Knotless Tissue Control Devices Market share in 2025. Their leading position follows the directional workflow used in robotic surgery. Robotic surgeons commonly close tissue from a defined reference point in one direction. Unidirectional barbs permit forward passage and resist backward movement. This design matches the closure performed through a confined robotic workspace. The architecture also reduces dependence on repeated knot tying during the closure run.

Bidirectional devices allow closure from the center of a wound toward both ends. They remain relevant for longer wounds and laparotomy cases in open-surgery settings, where symmetrical tension distribution can be valuable. Robotic growth reinforces unidirectional designs even though bidirectional products can offer theoretical benefits for symmetric wound management. The robotic workflow reduces the practical value of two-direction closure in the settings growing most quickly. B. Braun’s Aesculap division is conducting the BARHYSTER randomized trial, which compares Symmcora with Medtronic’s V-Loc in laparoscopic total hysterectomy. The study focuses competitive attention on the dominant unidirectional architecture in the Knotless Tissue Control Devices Market.

Complete Report Scope:

• By Product Type
  • Short-Term Absorbable Devices
  • Long-Term Absorbable Devices
  • Non-Absorbable Polymer Devices
• By Barb Architecture
  • Unidirectional Barbed Devices
  • Bidirectional Barbed Devices
• By Anchor Design
  • Loop-End Devices
  • Fixation-Tab Devices
  • End-Stopper Devices
• By Application
  • General Surgery
  • Gynecological and Obstetric Surgery
  • Orthopedic and Soft-Tissue Surgery
  • Cardiovascular Surgery
  • Urological Surgery
  • Cosmetic and Plastic Surgery
  • Colorectal and Bariatric Surgery
  • Other Applications
• By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Trauma Centers
  • Specialty Surgical Clinics
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 41.61% of the global Knotless Tissue Control Devices Market share in 2025. The United States supports this position through high robotic-surgery penetration and a mature ambulatory surgical center sector. The FDA pathway for Class II suture devices supported 6 related clearances between September 2025 and May 2026. This activity sustained product-cycle momentum and included established U.S. suppliers as well as entrants from India and South Korea. Canada has a more deliberate adoption path shaped by health technology assessment timelines. Mexico’s expanding private-hospital base supports wider use of minimally invasive techniques, although device penetration remains at an earlier stage.

Europe has a distinct demand environment because compliance requirements shape the pace of product entry. EU MDR 2017/745 requires updated clinical evidence for soft-tissue fixation products at recertification. This requirement adds time and cost that favor well-resourced suppliers and can restrict smaller entrants. The United Kingdom’s National Health Service targets 500,000 robotic surgeries each year by 2035, creating a long-term demand base for robotic-compatible closure. Serag-Wiessner, B. Braun, Resorba Medical, and Advanced Medical Solutions are established regional participants. Rest of Europe also follows the wider OECD shift toward ambulatory surgery, which extends demand beyond hospital-centered applications.

Asia-Pacific is forecast to grow at a 7.65% CAGR through 2031, the highest rate among geographic segments. China, Japan, India, South Korea, and Australia are the key countries supporting this growth. Smith+Nephew began commercial sales of the Q-FIX Knotless Anchor in Japan in March 2026 for shoulder, elbow, hip, knee, and ankle soft-tissue repair. Meril Endo Surgery received FDA clearance for the PINION PDO Knotless Suture in September 2025, positioning India as a cost-competitive manufacturing source with access to high-value export markets. Feeltech received U.S. clearance for a barbed surgical suture in October 2025, reflecting South Korea’s medical-device export capability. Hospital expansion in China and India is creating first-time demand for advanced closure across patient groups that historically used conventional sutures. The Middle East and Africa and South America are developing demand centers, with GCC private hospitals and procedure volumes in Brazil and Argentina providing the main regional support.

List of Companies Covered in this Report:

• Advanced Medical Solutions Group
• B. Braun
• Conmed
• Corza Medical
• DemeTECH
• Dolphin Sutures
• Genesis MedTech Group
• Healthium Medtech Limited
• Johnson & Johnson
• Medtronic
• Serag-Wiessner GmbH & Co. KG
• Shandong Weigao Group Medical Polymer Company Limited
• Smith+Nephew plc
• Stryker
• Teleflex
• UNIFY Surgical

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support